Waters Launches Cyclic IMS P20 MS, Boosting Disease Detection and Biotherapeutics Development
Event summary
- Waters Corporation launched the Cyclic IMS P20 Mass Spectrometer, a high-resolution structural and spatial omics platform, on June 1, 2026.
- The new system offers a >10x increase in MS/MS sensitivity and a 50% extended upper mass range compared to its predecessor.
- The platform integrates MALDI XS and DESI XS imaging with high-resolution ion mobility for direct visualization of molecules in tissue.
- The Cyclic IMS P20 MS is expected to be available globally beginning September 2026.
The big picture
Waters' Cyclic IMS P20 MS represents a significant leap in mass spectrometry technology, addressing the growing need for higher sensitivity and structural resolution in biotherapeutics development and disease detection. This launch aligns with the broader industry trend towards precision medicine and the increasing complexity of therapeutic targets. The platform's ability to reveal subtle biological differences could accelerate therapeutic breakthroughs and improve early disease detection.
What we're watching
- Adoption Pace
- The pace at which academic and industry researchers will integrate the Cyclic IMS P20 MS into their workflows, particularly for low-abundance species analysis.
- Competitive Response
- How competitors like Thermo Fisher Scientific and Agilent Technologies will react to Waters' technological advancements in structural and spatial omics.
- Market Expansion
- Whether the enhanced capabilities of the Cyclic IMS P20 MS will drive significant growth in the structural and spatial omics market.
Related topics